Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation.

Borko Amulic, Sebastian Lorenz Knackstedt, Ulrike Abu Abed, Nikolaus Deigendesch, Christopher J. Harbort, Brian E. Caffrey, Volker Brinkmann, Frank L. Heppner, Philip W. Hinds, Arturo Zychlinsky, Cell-Cycle Proteins Control Production of Neutrophil Extracellular Traps. Developmental Cell. ,vol. 43, pp. 449- 462 ,(2017) , 10.1016/J.DEVCEL.2017.10.013

Yu-Han Huang, Caoqi Fan, Shancheng Ren, Yinghao Sun, Gordon J. Freeman, Piotr Sicinski, Wenyi Wei, Jinfang Zhang, Xia Bu, Haizhen Wang, Yasheng Zhu, Yan Geng, Naoe Taira Nihira, Yuyong Tan, Yanpeng Ci, Fei Wu, Xiangpeng Dai, Jianping Guo, Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance Nature. ,vol. 553, pp. 91- 95 ,(2018) , 10.1038/NATURE25015

Xueqian Gong, Lacey M. Litchfield, Yue Webster, Li-Chun Chio, Swee Seong Wong, Trent R. Stewart, Michele Dowless, Jack Dempsey, Yi Zeng, Raquel Torres, Karsten Boehnke, Cecilia Mur, Carlos Marugán, Carmen Baquero, Chunping Yu, Steven M. Bray, Isabella H. Wulur, Chen Bi, Shaoyou Chu, Hui-Rong Qian, Philip W. Iversen, Farhana F. Merzoug, Xiang S. Ye, Christoph Reinhard, Alfonso De Dios, Jian Du, Charles W. Caldwell, María José Lallena, Richard P. Beckmann, Sean G. Buchanan, Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib Cancer Cell. ,vol. 32, pp. 761- ,(2017) , 10.1016/J.CCELL.2017.11.006

David A. Schaer, Richard P. Beckmann, Jack A. Dempsey, Lysiane Huber, Amelie Forest, Nelusha Amaladas, Yanxia Li, Ying Cindy Wang, Erik R. Rasmussen, Darin Chin, Andrew Capen, Carmine Carpenito, Kirk A. Staschke, Linda A. Chung, Lacey M. Litchfield, Farhana F. Merzoug, Xueqian Gong, Philip W. Iversen, Sean Buchanan, Alfonso de Dios, Ruslan D. Novosiadly, Michael Kalos, The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade. Cell Reports. ,vol. 22, pp. 2978- 2994 ,(2018) , 10.1016/J.CELREP.2018.02.053

Silvia Paola Corona, Daniele Generali, Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2- advanced breast cancer. Drug Design Development and Therapy. ,vol. 12, pp. 321- 330 ,(2018) , 10.2147/DDDT.S137783

Claudia Fumarola, Pier Giorgio Petronini, Roberta Alfieri, Impairing energy metabolism in solid tumors through agents targeting oncogenic signaling pathways. Biochemical Pharmacology. ,vol. 151, pp. 114- 125 ,(2018) , 10.1016/J.BCP.2018.03.006

Se Jin Oh, Hanbyoul Cho, Suhyun Kim, Kyung Hee Noh, Kwon-Ho Song, Hyo-Jung Lee, Seon Rang Woo, Suyeon Kim, Chel Hun Choi, Joon-Yong Chung, Stephen M. Hewitt, Jae-Hoon Kim, Seungki Baek, Kyung-Mi Lee, Cassian Yee, Hae-Chul Park, Tae Woo Kim, Targeting Cyclin D-CDK4/6 sensitizes immune-refractory cancer by blocking the SCP3-NANOG axis Cancer Research. ,vol. 78, pp. 2638- 2653 ,(2018) , 10.1158/0008-5472.CAN-17-2325

Daniele Cretella, Andrea Ravelli, Claudia Fumarola, Silvia La Monica, Graziana Digiacomo, Andrea Cavazzoni, Roberta Alfieri, Alessandra Biondi, Daniele Generali, Mara Bonelli, Pier Giorgio Petronini, The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells Journal of Experimental & Clinical Cancer Research. ,vol. 37, pp. 1- 12 ,(2018) , 10.1186/S13046-018-0741-3

Mary E. Klein, Marta Kovatcheva, Lara E. Davis, William D. Tap, Andrew Koff, CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought. Cancer Cell. ,vol. 34, pp. 9- 20 ,(2018) , 10.1016/J.CCELL.2018.03.023

Sarwat Naz, Anastasia Sowers, Rajani Choudhuri, Maria Wissler, Janet Gamson, Askale Mathias, John A. Cook, James B. Mitchell, Abemaciclib, a Selective CDK4/6 Inhibitor, Enhances the Radiosensitivity of Non–Small Cell Lung Cancer In Vitro and In Vivo Clinical Cancer Research. ,vol. 24, pp. 3994- 4005 ,(2018) , 10.1158/1078-0432.CCR-17-3575